3Hogg JC,Chu F,Utokaparch S,et al.The nature of small-airway obstruction in chronic obstructive pulmonary disease[J].N Engl J Med,2004,350:2645-2653.
4Mahler DA,Wire P,Horstman D,et al.Effectiveness of fluticasone tropionate and salneterol combination delivered via the Diskus device in the treatment of COPD[J].Am J Respir Crit Care Med,2002,166(8):1084-1091.
3Pauwels RA,Buist AS,Calverley PM,et al. Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med,2001,163:1256-1276.
4Gross NJ. Outcome measures for COPD treatments:a critical evaluation. COPD,2004,1:41-57.
5Celli BR,MacNee W,ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J,2004,23:932-946.
6Marin JM,Carrizo SJ,Gascon M,et al. Inspiratory capacity,dynamic hyperinflation,breathlessness,and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2001,163:1395-1399.
7Redelmeier DA,Bayoumi AM,Goldstein RS,et al. Interpreting small differences in functional status:the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med,1997,155:1278-1282.
8Curtis JR,Patrick DL. The assessment of health status among patients with COPD. Eur Respir J Suppl,2003,41:36s-45s.
9Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest,2000,117(5 Suppl 2):398S-401S.
10Kharitonov SA,Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med,2001,163:1693-1722.
